Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

This study tested a new molecular tool (called a "response classifier") that analyzes a patient's biology to predict which type of medication

Duration

~ 6 months

Visits

6 – 8 clinic visits

Compensation

Yes, Provided

Location

Bellevue, WA

About This Trial

This study tested a new molecular tool (called a “response classifier”) that analyzes a patient’s biology to predict which type of medication — a JAK inhibitor, T-cell inhibitor, or IL-6 inhibitor — is most likely to work for them.

The goal was to move toward more personalized treatment for rheumatoid arthritis, rather than a one-size-fits-all approach. Participants provided samples that were used to evaluate the classifier’s ability to predict treatment response.

Condition: Rheumatoid Arthritis

Learn more: View Protocol/Consent Form (PDF)

Check Your Eligibility Screening

Answer a few questions to see if you may qualify for our gout clinical trial.

Eligibility screening is not available at the moment.

This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.

Other Trials

We have several clinical trials and you may be eligible for more than one. Lets find out.

Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

This study tested a new molecular tool (called a "response classifier") that analyzes a patient's biology to predict which type of medication

About This Trial

Check Your Eligibility Screening

Other Trials

Evaluating Sarilumab for Adults with Early Polymyalgia Rheumatica (PMR)

Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis

Continued Secukinumab Treatment for Prior Novartis Study Participants

V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

Testing a New Combination Treatment for Gout

Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis

Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication

AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis

Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease

Testing Afimetoran for Active Lupus (SLE)

Phase 3 Study of AR882 for Gout